References

• Achan, J., Talisuna, A. O., Erhart, A., Yeka, A., Tibenderana, J. K., Baliraine, F. N., D’Alessandro, U. (2011). Quinine, an old antimalarial drug in a modern world: role in the treatment of malaria. Malaria Journal, 10(1), 144.
• Adagu, i. s., & warhurst, D. C. (1999). Association of cg2 and pfmdr1 genotype with chloroquine resistance in field samples of Plasmodium falciparum from Nigeria. Parasitology 119, 343-348
• Asih, P. B., Rogers, W. O., Susanti, A. I., Rahmat, A., Rozi, I. E., Kusumaningtyas, M. A., Dewi, R. M., Coutrier, F. N., Sutamihardja, A., van der Ven, A. J., & Sauerwein, R. W. (2009). Seasonal distribution of antimalarial drug resistance alleles on the island of Sumba, Indonesia. Malaria journal, 8(1), pp.1-7.
• Basco, L. K. (2007). Field application of in vitro assays for the sensitivity of human malaria parasites to antimalarial drugs. Geneva World Health Organization Cop
• Berens, N., Schwoebel, B., Jordan, S., Vanisaveth, V., Phetsouvanh, R., Christophel, E. M., Phompida, S., Jelinek, T. (2003). Plasmodium falciparum: correlation of in vivo resistance to chloroquine and Antifolate with genetic polymorphisms in isolates from the south of Lao PDR. Trop Med Int Health 8,775–782
• Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., & Ringwald, P. (2009). Artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine, 361(5), pp.455-467
• Eckstein-Ludwig, U., Webb, R. J., van Goethem, I. D. A., East, J. M., Lee, A. G., Kimura, M., & Krishna, S. (2003). Artemisinins target the SERCA of Plasmodium falciparum. Nature, 424(6951), 957–961. doi:10.1038/nature01813.
• Fivelman, Q. L., Butcher, G. A., Adagu, I. S., Warhurst, D. C., & Pasvol, G. (2002). Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malaria journal, 1(1), pp.1-4.
• Gowda, D. C., Dayananda, K., & Achur, R. (2018). Epidemiology, drug resistance, and pathophysiology of Plasmodium vivax malaria. Journal of Vector Borne Diseases, 55(1), p.1)
• Haldar, K., Bhattacharjee, S., & Safeukui, I. (2018). Drug resistance in Plasmodium. Nature Reviews Microbiology, 16(3), 156–170.
• Jomaa, H., Wiesner, J., Sanderbrand, S., Altincicek, B., Weidemeyer, C., Hintz, M., Türbachova, I., Eberl, M., Zeidler, J., Lichtenthaler, H. K., & Soldati, D. (1999). Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science, 285(5433), pp.1573-1576.
• Koenderink, J. B., Kavishe, R. A., Rijpma, S. R., & Russel, F. G. M. (2010). The ABCs of multidrug resistance in malaria. Trends in Parasitology, 26(9), 440–446.
• Na-Bangchang, K., & Congpuong, K. (2007). Current Malaria Status and Distribution of Drug Resistance in East and Southeast Asia with Special Focus to Thailand. The Tohoku Journal of Experimental Medicine, 211(2), 99–113.
• Nuno Vale, A., Rui Moreira, b., Paula Gomes. (2009). Primaquine revisited six decades after its discovery. European Journal of Medicinal Chemistry, 44,937–953
• Organisation Mondiale De La Santé . (2010). Global report on antimalarial drug efficacy and drug resistance: 2000-2010. Geneva: World Health Organization. C.
• Parija, S., & Praharaj, I. (2011). Drug resistance in malaria. Indian Journal of Medical Microbiology, 29(3), p.243.
• Price, R. N., Uhlemann, A. C., Brockman, A., McGready, R., Ashley, E., Phaipun, L., & Krishna, S. (2004). Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. The Lancet, 364(9432), 438–447. doi:10.1016/s0140- 6736(04)16767-6.
• Rathore, D., McCutchan, T. F., Sullivan, M., & Kumar, S. (2005). Antimalarial drugs: current status and new developments. Expert Opinion on Investigational Drugs, 14(7), 871–883. doi:10.1517/13543784.14.7.871
• Ross, L. S., & Fidock, D. A. (2019). Elucidating Mechanisms of Drug-Resistant Plasmodium falciparum. Cell Host & Microbe, 26(1), 35–47
• Schlitzer, M. (2008). Antimalarial Drugs – What is in Use and What is in the Pipeline. Archiv Der Pharmazie, 341(3), 149–163.
• Shibeshi, M. A., Kifle, Z. D., & Atnafie, S. A. (2020). Antimalarial drug resistance and novel targets for antimalarial drug discovery. Infection and Drug Resistance, 13, p.4047.
• Sumawinata, I. W., Leksana, B., Sutamihardja, A., Subianto, B., Fryauff, D. J., & Baird, J. K. (2003. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. The American journal of tropical medicine and hygiene, 68(4), pp.416-420.
• Syafruddin, D., Asih, P. B., Aggarwal, S. L., & Shankar, A. H. (2003). Frequency distribution of antimalarial drug-resistant alleles among isolates of Plasmodium falciparum in Purworejo district, Central Java Province, Indonesia. The American journal of tropical medicine and hygiene, 69(6), pp.614-620.
• asanor, O., Ruengweerayut, R., Sirichaisinthop, J., Congpuong, K., Wernsdorfer, W. H., & Na- Bangchang, K. (2006). Clinical-parasitological response and in-vitro sensitivity of Plasmodium vivax to chloroquine and quinine on the western border of Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 100(5), pp.410-418
• Uhlemann, A. C., & Krishna, S. (2005). Antimalarial multi- drug resistance in Asia: mechanisms and assessment. Malaria: Drugs, Disease and Post-genomic Biology, pp.39-53.
• Von Seidlein, L., Duraisingh, M. T., Drakeley, C. J., Bailey, R., Greenwood, B. M., & Pinder, M. (1997).Polymorphism of the Pfmdr1 gene and chloroquine resistance in Plasmodium falciparum in The Gambia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 91(4), 450–453. doi:10.1016/s0035- 9203(97)90281-9.
• White, N. J., Pukrittayakamee, S., Hien, T. T., Faiz, M. A., Mokuolu, O. A., & Dondorp, A. M. (2014). Malaria. The Lancet, 383(9918), 723–735. doi:10.1016/s0140- 6736(13)60024-0
• White, Nicholas J. (2004). Antimalarial drug resistance. Journal of Clinical Investigation, 113(8), 1084–1092.
• Wiesner, J., Ortmann, R., Jomaa, H., & Schlitzer, M., (2003). New antimalarial drugs. Angewandte Chemie International Edition, 42(43), pp.5274-5293
• World Health Organization. (2015). Guidelines for the treatment of malaria. World Health Organization.
• World Health Organization. Global report on antimalarial drug efficacy and drug resistance: 2000–2010
• World Health Organization. World Malaria Report 2016 (WHO, 2016
• Yuthavong, Y. (2002). Basis for antifolate action and resistance in malaria. Microbes and Infection, 4(2), 175–182
• Zhang, R., Suwanarusk, R., Malleret, B., Cooke, B. M., Nosten, F., Lau, Y. L., Dao, M., Lim, C. T., Renia, L., Tan, K. S. W., & Russell, B. (2016.) A basis for rapid clearance of circulating ring-stage malaria parasites by the spiroindolone KAE609. The Journal of infectious diseases, 213(1), pp.100-104.